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Abstract
Background—Ketoconazole is a well-known CYP-17-targeted systemic treatment for 
castration-resistant prostate cancer (CRPC). However, most of the published data has been in the 
pre-chemotherapy setting; its efficacy in the post-chemotherapy setting has not been as widely 
described. Chemotherapy-naïve patients treated with attenuated doses of ketoconazole (200-300 
mg three times daily) had prostate specific antigen (PSA) response rate (greater than 50% decline) 
of 21% to 62%. We hypothesized that low-dose ketoconazole would likewise possess efficacy and 
tolerability in the CRPC post-chemotherapy state.
Methods—Men with CRPC and performance status (PS) 0-3, adequate organ function and who 
had received prior docetaxel were treated with low-dose ketoconazole (200 mg PO three times 
daily) and hydrocortisone (20 mg PO qAM and 10 mg PO qPM) until disease progression. 
Primary endpoint was PSA response rate (greater than 50% reduction from baseline) where a PSA 
response rate of 25% was to be considered promising for further study (versus a null rate of less 
than 5%); 25 patients were required. Secondary endpoints included PSA response greater than 
30% from baseline, progression-free survival (PFS), duration of stable disease, and evaluation of 
adverse events (AEs).
Results—Thirty patients were accrued with median age of 72 years (range 55-86) and median 
pre-treatment PSA of 73 ng/ml (range 7-11,420). Twenty-nine patients were evaluable for 
response and toxicity. PSA response (>50% reduction) was seen in 48% of patients; PSA response 
(>30% reduction) was seen in 59%. Median PFS was 138 days; median duration of stable disease 
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was 123 days. Twelve patients experienced grade 3 or 4 AEs. Of the 17 grade 3 AEs, only 3 were 
attributed to treatment. None of the 2 grade 4 AEs was considered related to treatment.
Conclusions—In docetaxel pre-treated CRPC patients, low-dose ketoconazole and 
hydrocortisone is a well-tolerated, relatively inexpensive and clinically active treatment option. 
PSA response to low-dose ketoconazole appears historically comparable to that of abiraterone in 
this patient context. A prospective, randomized study of available post-chemotherapy options is 
warranted to assess comparative efficacy.
Introduction
In 2014, the National Cancer Institute's SEER database estimates that 233,000 men in the 
United States will be diagnosed with prostate cancer and 29,480 patients will die from this 
disease. While the majority of patients will have early stage prostate cancer, a proportion of 
these patients will progress and develop metastasis and a small fraction of men will be 
diagnosed with metastatic disease at the outset. Androgen deprivation therapy (ADT) using 
luteinizing hormone releasing hormone (LHRH) agonists (with or without androgen receptor 
[AR] antagonists) is considered standard first-line treatment in patients with locally 
advanced or metastatic disease. Although all metastatic prostate cancer patients will 
eventually progress despite ADT to a ‘castration-resistant’ state, the disease remains 
androgen receptor-driven and hence still potentially responsive to modulation of hormonal 
pathways.
Traditional hormonal manipulation in the castrate-resistant context, including ketoconazole, 
megestrol and AR antagonists (bicalutamide, nilutamide and flutamide) have been often 
used in CRPC, however none had been shown to prolong survival until recently with newer 
agents such as abiraterone and enzalutamide. Ketoconazole, an oral antifungal agent, was 
first described to have activity in prostate cancer over 30 years ago and has long been used 
off-label in the treatment of CRPC prior to docetaxel. It blocks androgen synthesis by 
inhibiting the C17,20-desmolase enzyme, a key microsomal cytochrome P450-dependent 
enzyme, necessary for adrenal androgen and testosterone biosynthesis. It is also suspected to 
have direct cytotoxic effects on prostate cancer cells by inhibiting DNA synthesis in-vitro 
and to possibly induce G0/G1 cell cycle arrest in other cancers.[1-3] High-dose 
ketoconazole therapy with 400 mg three-times daily and replacement hydrocortisone has 
become the standard dose schedule. However, toxicities (some due to off-target effects) 
including fatigue, abdominal pain, hepatic dysfunction, nausea, diarrhea, and mucositis have 
often limited its long-term use.[4] Low-dose ketoconazole at 200 mg three times daily and 
intermediate-dose ketoconazole at 300 mg three times daily have been explored in the pre-
chemotherapy setting with comparable response rates (28% to 55%) to high-dose 
ketoconazole and better tolerability.[5-7]
Cytotoxic chemotherapy was considered relatively ineffective in CRPC until two landmark 
clinical trials established a survival benefit for docetaxel in this setting.[8, 9] Docetaxel 
subsequently received FDA approval in 2004 and subsequently became a standard of care in 
metastatic CRPC treatment. Despite progression on ADT, castration-resistant disease 
continues to rely on androgen pathways within the tumor, testes, and adrenal glands for 
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growth, reaffirming the key role of the AR and AR signaling in the progression of prostate 
cancer throughout the course of the disease. CYP17 plays a crucial role within the androgen 
biosynthesis pathway and is the target of androgen synthesis inhibitors such as ketoconazole 
and abiraterone. Abiraterone received FDA approval in 2011 after showing a survival 
benefit in docetaxel pre-treated CRPC patients with expanded approval in 2013 for its use 
prior to docetaxel.[10, 11] Similar to other AR antagonists, enzalutamide binds to AR, but is 
unique in its ability to also inhibit AR nuclear translocation and interaction with DNA. 
Enzalutamide received FDA approval in 2013 after showing a survival benefit in docetaxel 
pre-treated CRPC patients.[12]
Most of the published data for ketoconazole (with few exceptions[13, 14]) has been in an era 
when patients benefiting from ketoconazole had not yet received any prior chemotherapy. 
This study was conducted to prospectively assess the response rate to low-dose ketoconazole 
after CRPC patients had received at least one prior chemotherapy regimen.
Methods
Patients
Inclusion criteria—Eligible patients must have had biopsy-proven prostate cancer 
deemed to be castrate-resistant despite androgen deprivation and have evidence of either 
radiographic progression or rising PSA (two consecutive rises at least two weeks apart). 
Other major eligibility criteria included age at least 18 years old and Zubrod performance 
status of 0-3 with adequate end-organ and marrow function.
They must have received at least one prior docetaxel-based regimen more than 3 weeks prior 
to initiation of study. Patients must have been surgically or medically castrated with a total 
serum testosterone level less than 50 ng/dL. If the method of castration was LHRH agonists 
(leuprolide or goserelin), then the patient must have been willing to continue the use of 
LHRH agonists. If the patient had been treated with non-steroidal anti-androgens (flutamide, 
bicalutamide or nilutamide) or other hormonal treatment (megestrol acetate or steroids), the 
patient must have stopped these agents at least 28 days prior to enrollment for flutamide, 
megestrol or steroids and at least 42 days prior to enrollment for bicalutamide or nilutamide; 
patients must have demonstrated progression of disease since these agents were suspended.
Exclusion criteria—Patients could not have had any prior treatment with ketoconazole 
for prostate cancer or have had any other active malignancies in the past 3 years except non-
melanoma skin cancer. They were ineligible if they could not take oral medications or had a 
known hypersensitivity to ketoconazole. Patients were not allowed to take certain 
medications, including terbinafine, astemizole, triazolam, statins (except pravastatin and 
fluvastatin) and acid suppressive agents (antacids, H2 blockers, proton pump inhibitors) 
while on trial given the known interactions with ketoconazole.
Study Design
This was an open-label, single-institution investigator initiated phase II study sponsored by 
the University of California Davis Comprehensive Cancer Center Support Grant. CRPC 
patients received ketoconazole, administered orally at a dose of 200 mg three times a day, 
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and hydrocortisone, administered orally at 20 mg in the morning and 10 mg in the evening. 
Each treatment cycle was 28 days and treatment was continued until disease progression, 
unacceptable toxicity despite dose reduction, death, or upon the patient or physician's 
discretion.
Adverse events that resolved promptly with supportive care required no dosing adjustment. 
For grade 3 or higher AE related to ketoconazole that did not resolve to grade 2 or less 
despite maximum supportive care for 72 hours, ketoconazole was held until resolution of 
AE to grade 2 or less and then continued at one dose level reduction. The ketoconazole dose 
would be reduced from an initial 200 mg three times/day to 200 mg twice/day and if 
necessary to 100 mg three times/day; no additional reductions were permitted after this last 
dose level reduction and patients would subsequently be removed from the study if still 
intolerant. Patients with grade 3 AE that did not resolve to grade 2 at the lowest reduced 
dose level were removed from study.
Assessments
Physical examinations and blood tests were completed as close as possible to the study 
enrollment date (within 28 days) and then at four-week intervals thereafter. For patients with 
measurable disease, imaging studies were done every 8 weeks. Serum PSA was measured at 
time of study enrollment and every 4 weeks. PSA progression was defined as an increase in 
PSA by at least 50% over the nadir or baseline (pretreatment) value, whichever was lower. 
The lowest PSA value at any timepoint was recorded as best response.
Adverse events were classified according to the National Cancer Institute CTCAE 3.0 
Common Terminology Criteria (CTC). Serious AE were fatal or life-threatening, resulted in 
prolonged or substantial disability, required hospitalization. Patients were followed for 8-12 
weeks after removal from study or until death, whichever occurred first. Patients removed 
from study for unacceptable AE were followed until resolution or stabilization of the 
adverse event.
Statistical Considerations
The primary endpoint was PSA response defined as greater than 50% reduction from 
baseline. The lowest PSA achieved at any point was recorded. Secondary endpoints included 
PSA response (greater than 30% from baseline), progression-free survival (PFS) defined as 
time from registration until disease progression employing RECIST radiographic criteria for 
progression (i.e., PCWG2 criteria were not used for this study), duration of stable disease 
defined as time from start of treatment until disease progression, and safety. Imaging studies 
(CT and/or bone scans) were performed after every 8 weeks in patients with measurable or 
evaluable disease. To estimate the planned sample size, a single-arm Simon single-stage 
phase II minimax design was employed. A sample size of 25 patients had a power of at least 
90% to detect PSA response in greater than 25% of patients versus the null hypothesis of a 
PSA response in less than 5% of patients. To account for dropouts, a target of 30 patients 
was recruited for this study.
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Results
Patient Characteristics
Between November 2009 and December 2013, we enrolled 30 patients with CRPC who had 
failed at least one line of docetaxel-based chemotherapy. The date of data cutoff was 
December 2013. Table 1 summarizes the baseline patient characteristics of all 30 patients, of 
which 29 patients were evaluable for treatment response and AE at time of data cutoff. The 
median age of the patients was 72 years with a range from 55-86 years. All patients had 
Zubrod PS of 0-1 except for one (PS 2). Baseline pre-study PSA was 73 ng/ml with a wide 
range 7-11,420 ng/ml. Median values of hemoglobin were 12.8 g/dL, alkaline phosphatase 
of 96 U/L and creatinine of 0.87 mg/dl.
Two patients had received systemic chemotherapy in addition to docetaxel (cabazitaxel or 
vinorelbine) prior to study entry. Six patients had received prior androgen synthesis 
inhibitors, four with abiraterone and two with orteronel. One patient had previously received 
enzalutamide. Four patients had received immunotherapy with sipuleucel-T. Five patients 
had received prior biologic therapy including one patient with cabozantinib, one patient with 
siltuximab, and three patients with atrasentan.
Outcomes/Efficacy
A waterfall plot of the best PSA response (>50% decline from baseline) among the 29 
evaluable patients (Figure 1) showed that 14 (48%) patients experienced PSA response. A 
total of 17 (59%) patients experienced at least 30% decline in their PSA (Table 2). 
Responses were durable with a median PFS of 138 days (4.6 months) while duration of 
stable disease was 123 days (Table 2). Figure 2 shows the Kaplan-Meier curve for PFS with 
95% confidence intervals.
Adverse Events
The incidence of grade 3 or 4 AE is shown in table 3. The most frequently reported grade 3 
or 4 AE was cardiotoxicity (4 patients), followed equally by hepatoxicity, neurotoxicity, 
electrolyte disturbance, malaise/fatigue, and pain. Thirteen unique patients experienced at 
least one AE; an AE led to discontinuation of low-dose ketoconazole in one patient. No 
deaths occurred while the patient was receiving the study drug. The three Grade 3 toxicities 
considered possibly or probably related to treatment included hyperglycemia, elevated 
aspartate aminotransferase, and fatigue. No grade 4 toxicities were attributed to treatment.
Discussion
In this single-arm phase II trial, the efficacy of low-dose ketoconazole was studied in men 
with CRPC who had failed ADT and had undergone at least one line of docetaxel-based 
chemotherapy. The characteristics of patients in this trial were typical of those commonly 
seen in the clinical oncology practice. Most patients had bone metastases and high serum 
PSA. We found that PSA response rates, PFS, and duration of response all suggest 
reasonable efficacy for low-dose ketoconazole in this chemotherapy-pretreated setting. Low-
dose ketoconazole demonstrated PSA response (>50% from baseline) of 49%, which 
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appears at least comparable to that seen in the only phase III randomized study of high-dose 
ketoconazole (response rate of 32% in pre-docetaxel CRPC).[15] The PSA response rate in 
this study also appears similar to those described in aforementioned phase III studies of 
newer hormonal therapies such as abiraterone (29%) and enzalutamide (54%) in the post-
docetaxel setting.[10, 12] However, median PFS of 4.6 mos (138 days) was somewhat less 
than that observed with abiraterone (5.6 mos) or enzalutamide (8.3 mos), although our study 
was limited by its use of RECIST-based PFS criteria. Furthermore, in a recent retrospective 
study, men with docetaxel pre-treated CRPC who then received either abiraterone or 
ketoconazole were analyzed.[16] In that study, outcomes such as PSA response and PFS 
(either biochemical or radiological) appeared to favor patients treated with abiraterone, 
although overall survival was not statistically different between the groups.
While mature overall survival (OS) data are not yet available at time of data cutoff, a PSA 
response greater than 30% from baseline was seen in 59% of patients. Prior reports suggest 
that a PSA decline of this magnitude may potentially be associated with subsequent OS 
benefit, despite some controversy surrounding the use of PSA as an intermediate marker of 
disease response and outcome.[17, 18] Further complicating comparisons of treatment 
benefit, especially OS, is the ‘cross-contamination’ of the placebo arm with subsequent lines 
of active therapy. This was seen in a phase III study of the novel CYP17 inhibitor orteronel 
compared to placebo, which showed a significant PFS but no OS benefit.[19] One likely 
reason was that many in the placebo arm were treated upon progression with abiraterone, an 
agent similar to orteronel. It is highly likely that any future randomized trial of low-dose 
ketoconazole versus placebo might also witness the same confounding effect.
Given the relative abundance of treatment options in CRPC, one important question is the 
optimal sequence of therapy. There is data suggesting that docetaxel's anti-tumor effect 
comes in part from its ability to suppress AR expression and that cross-resistance is seen 
when docetaxel is used after abiraterone.[20] With abiraterone, a recent trial has shown 
decreased PSA response and median PFS when used after enzalutamide, but not in every 
patient.[21] When sequential therapies targeting the AR pathway show decreased efficacy, 
this suggests some degree of acquired resistance despite different mechanisms of action and 
highlights the current gaps in our understanding. In a large retrospective study on the effect 
of prior ketoconazole on subsequent docetaxel therapy, there was no apparent difference in 
survival between men receiving prior ketoconazole or not.[22] Identifying those patients 
most likely to benefit from androgen synthesis inhibitors or AR antagonists would be one 
way that subsequent trials can help define the optimal sequence of therapies in the CRPC 
setting.
In the current and future healthcare landscape, the cost per quality adjusted life year 
(QALY) may become as important as OS, PFS, and response rate when evaluating a 
therapy's overall efficacy. From this perspective, a generic drug like ketoconazole has the 
potential to compare favorably to newer and more expensive agents. A recent formal study 
of abiraterone vs placebo calculated the cost at $94,000/QALY.[23] It must be noted that 
ketoconazole is a generic medication and while the QALY for ketoconazole has not to our 
knowledge been formally studied, the cost for a one-month supply of low-dose ketoconazole 
Lo et al. Page 6
Prostate Cancer Prostatic Dis. Author manuscript; available in PMC 2015 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
(200 mg tab, three times daily) is $193, based on acquisition costs at this institution as of 
this writing.
Encouragingly, low-dose ketoconazole was well-tolerated in almost all patients with the vast 
majority of AEs being grade 1 or 2 and only one patient had to withdraw due to treatment 
intolerance. None of the grade 4 AE was thought related to the study treatment and no 
patients died while on treatment.
This study had several limitations. It is a single-institution trial with a modest sample size. 
Furthermore, RECIST criteria (and not PCWG2) were used, and confirmation of PSA 
response was not required. Another limitation was the lack of a double-blind design that 
required us instead to rely on external trials as a comparator. While low-dose ketoconazole 
appears to have activity in this setting, it is also important to recognize that part of this 
response might be attributable to concurrent hydrocortisone, which is needed to replace 
decreased cortisol production while on ketoconazole. Replacement doses of hydrocortisone 
were shown in a large phase III trial to result in a PSA response in 16% of patients.[24]
To our knowledge, this is the first prospective study of the efficacy of low-dose 
ketoconazole in the post-docetaxel setting. Our findings provide evidence that low-dose 
ketoconazole has continued activity after docetaxel that may be comparable to high-dose 
ketoconazole, abiraterone, and enzalutamide. It appears to be a well-tolerated, relatively 
inexpensive and clinically active treatment option. A prospective randomized study is 
ultimately needed to assess the comparative efficacy, survival benefit, and cost effectiveness 
of low-dose ketoconazole against the newer AR-pathway inhibitors in this setting.
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Figure 1. Waterfall Plot of PSA Response
*indicates receipt of prior CYP inhibitor therapy (either abiraterone or orteronel)
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Figure 2. Kaplan-Meier Curve for Progression Free Survival
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Table I
Patient Characteristics
Characteristic Total (n = 30)
Median age, range (years) 72, 55 – 86
Zubrod Performance Status
 0 16
 1 13
 2 1
Median pre-treatment PSA, range (ng/ml) 73, 7 – 11,420
Median hemoglobin, range (g/dL) 12.8, 9.7 – 15.5
Median alkaline phosphatase, range (U/L) 96, 36 – 271
Median creatinine, range (mg/dL) 0.87, 0.60 – 1.83
Prior therapy (# patients)
 LHRH antagonist 30
 AR antagonist 30
 Docetaxel 30
 Cabazitaxel 1
 Vinorelbine 1
 Abiraterone 4
 Orteronel 2
 Enzalutamide 1
 Sipuleucel-T 4
 Atrasentan 1
 Silutuximab 1
 Cabozantanib 1
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Table 2
Efficacy
Efficacy Total (n = 29)
PSA response rate > 50% (# patients,%) 14, 48%
PSA response rate > 30% (# patients,%) 17, 59%
Median progression free survival (days) 138 (95% CI: 80, 260)
Median duration of stable disease (days) 123 (range: 2-728)
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Table 3
All Grade 3 or Grade 4 Adverse Events (CTCAE v3.0)
Event Grade 3 (# events) Grade 4 (# events)
Cardiac general Angina (1) Myocardial infarct (1)
Congestive heart failure (1) -
Myocarditis (1) -
Cardiac arrhythmia Atrial fibrillation (1) -
Constitutional symptoms Weight gain (2) -
Fatigue (1) -
Metabolic Transaminitis (2) Hyperkalemia (1)
Hyponatremia (1) -
Hyperglycemia (1) -
Musculoskeletal Fracture (1) -
Neurology Syncope (1) -
Mood alteration (1) -
Psychosis (1) -
Pain Pain (2) -
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